[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651793":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":49,"centralContacts":54,"locations":39,"responsibleParty":64,"collaborators":39,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":39,"enrollmentInfo":76,"targetDuration":39,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":89,"whyStopped":39,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":39},{"fullName":5,"class":6},"InSightec","INDUSTRY",[8,14,20,25,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Active Group 1_Unilateral Exablate Pallidothalamic Tractotomy","EXPERIMENTAL","Subjects will undergo the 1st side Exablate procedure (\\\u003C 30 days after randomization) and will be followed for 6 months. At their Month 6 visit, subjects will have their re-baseline assessment and undergo staged randomization for the 2nd side treatment.",[13],"Device: Unilateral Exablate MRgFUS Pallidothalamic Tractotomy",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group 1_Best Medical Treatment (BMT)","ACTIVE_COMPARATOR","Subjects will have their standard of care (SOC) treatment adjusted to best effect (BMT), and will be followed for 3 months. After their Month 3 visit, subjects will cross over to receive the 1st side treatment and be followed for 6 months. At their Month 6 visit, subjects will have their Treatment 2 re-baseline assessment and undergo staged randomization for the 2nd side treatment.",[19],"Drug: Best Medical Treatment (BMT)",{"label":21,"type":10,"description":22,"interventionNames":23},"Active Group 2_Staged Bilateral Exablate Pallidothalamic Tractotomy","Subjects will undergo the 2nd side Exablate procedure (\\\u003C 30 days after re-baseline assessment, and will be followed for 12 months.",[13,24],"Device: Staged Bilateral Exablate Pallidothalamic Tractotomy",{"label":26,"type":16,"description":27,"interventionNames":28},"Control Group 2_BMT after Unilateral Exablate Pallidothalamic Tractotomy","Subjects will continue with their SOC BMT and will be followed for 3 months. After their Month 3 visit, subjects will cross over to receive the 2nd side treatment and be followed for 12 months.",[13,19],{"label":30,"type":16,"description":31,"interventionNames":32},"Reference Group_BMT with low SDR","Subjects will be offered the option to receive best medical treatment and will be followed to capture natural disease progression at approximately the same time schedule as patients in the randomized groups (\\~ every 3 - 6 months for up to 24 months).",[19],[34,40,44],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DEVICE","Unilateral Exablate MRgFUS Pallidothalamic Tractotomy","1st side Exablate MRgFUS Pallidothalamic Tractotomy for Parkinson's Disease",[9,21,26],null,{"type":35,"name":41,"description":42,"armGroupLabels":43,"otherNames":39},"Staged Bilateral Exablate Pallidothalamic Tractotomy","2nd side staged Exablate MRgFUS Pallidothalamic Tractotomy for Parkinson's Disease",[21],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":39},"DRUG","Best Medical Treatment (BMT)","Subjects will be managed according to conventional therapeutic guidelines (i.e., best medical treatment) for Parkinson's Disease",[15,26,30],[50],{"name":51,"affiliation":52,"role":53},"Joohi Jimenez-shahed, MD","Mount Sinai, Clinical Neurosciences Center","PRINCIPAL_INVESTIGATOR",[55,60],{"name":56,"role":57,"phone":58,"phoneExt":39,"email":59},"Elisa Cerutti, PhD","CONTACT","+39 3459182413","elisac@insightec.com",{"name":61,"role":57,"phone":62,"phoneExt":39,"email":63},"Jai Shetake, PhD","+1 469 426 1022","jais@insightec.com",{"type":65,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100651793","unilateral-and-staged-bilateral-pallidothalamic-tractotomy-using-exablate-mrgfus-in-advanced-parkinsons-disease-100651793",false,"NCT07764874","Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.","An MR Guided Focused Ultrasound (MRgFUS) Randomized Trial Using the Exablate Neuro System to Assess the Effectiveness and Safety Outcomes of Unilateral and Staged Bilateral Ablation in the Subthalamic Region Involving the Pallidothalamic Tract (PTT) in Advanced Parkinson's Disease (PD) With Motor Complications.","FREEDOM","Inclusion Criteria:\n\n1. Men or women, age 30 years and older\n2. Subject is able and willing to give informed consent and able to attend all study visits\n3. Subject with a diagnosis of idiopathic PD by UK Brain Bank Criteria as confirmed by a movement disorder neurologist at the site.\n4. Subject is interested in receiving bilateral treatment if they qualify.\n5. Subject is Levodopa responsive as defined by at least a 30% reduction in MDS-UPDRS motor subscale in the ON vs OFF medication state.\n6. Subject has MDS-UPDRS Part III OFF ULE score of ≥ 15 on each side in the meds OFF condition.\n7. Subject experiencing motor complications of PD on optimum medical treatment characterized by dyskinesia (MDS-UPDRS item 4.2 score of ≥ 2) OR Motor fluctuations (MDS-UPDRS item 4.4 score of ≥ 2)\n8. Subject is on a stable dose of all PD medications for 30 days prior to screening visit PD assessments as determined by medical records\n9. Subject is able to communicate sensations during the Exablate procedure.\n10. Subject's pallidothalamic region can be targeted by the Exablate device.\n\nExclusion Criteria:\n\n1. Subject with severe premorbid risks as specified in the MDS-UPDRS Part II subsection motor aspects of experiences of daily living scores:\n\n   1. 3 or 4 on question 2.1 (speech) OR\n   2. 3 or 4 on question 2.3 (chewing and swallowing) OR\n   3. 4 on question 2.2 (saliva and drooling).\n2. Subject where there is suspicion that Parkinsonian symptoms are a side effect from neuroleptic medications.\n3. Subject has an MMSE score \\\u003C 24.\n4. Subject has other central neurodegenerative disease suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer's disease.\n5. Subject with unstable psychiatric disease, uncontrolled depressive symptoms, psychosis, delusions, hallucinations, or suicidal ideation.\n6. Female subject who is pregnant.\n7. Female subject of childbearing potential not willing to use contraceptives throughout the duration of the study (\\~ 24 months)\n8. Subject exhibiting any behavior(s) consistent with ethanol or substance abuse.\n9. Subject with unstable cardiac status or severe hypertension.\n10. Subject with history of abnormal bleeding, hemorrhage, or coagulopathy.\n11. Subject with cerebrovascular disease.\n12. Subject is receiving anticoagulant (e.g., warfarin) or antiplatelet (e.g., aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g., Avastin) within one month of focused ultrasound procedure.\n13. Subject with advanced kidney disease or on dialysis.\n14. Subject with a history of seizures within the past year.\n15. Subject with a brain tumor.\n16. Subject with life-threatening systemic disease (e.g. HIV, liver failure, blood dyscrasias, etc.).\n17. Subject with any illness that in the investigator's opinion precludes participation in this study.\n18. Subject with standard contraindications for MR imaging such as implanted metallic devices.\n19. Subject who had prior deep brain stimulation of the basal ganglia or thalamus.\n20. Subject who is unable to tolerate the required prolonged stationary supine position during treatment.\n21. Subject who has an Overall Skull Density Ratio of less than 0.40 as calculated from the screening CT (if this is the only exclusion, subject can participate in the study as part of the reference group).\n22. Subject who is participating in another clinical investigation with an active treatment arm\n23. Subject who is unable to communicate with the investigator and staff.\n24. Subject who is in a nursing home in the last 30 days.\n\n    Additional Exclusion Criteria for Staged Bilateral PTT procedure\n25. Clinically significant neurological event of dysphagia, abnormal speech function, or gait abnormalities that are moderate to severe following first procedure.","ALL","30 Years",{"count":77,"type":78},120,"ESTIMATED","INTERVENTIONAL",[81],"NA","This study is a randomized clinical trial evaluating a focused ultrasound treatment for people with advanced Parkinson's disease (PD) who have disabling motor complications and symptoms.\n\nThe study uses the Exablate Neuro System, which delivers MR-guided Focused Ultrasound (MRgFUS). This technology focuses ultrasound energy on a specific brain target and generates heat to create a small lesion (ablation) without making a surgical incision.\n\nThe target in this study is the Pallidothalamic Tract (PTT), a pathway involved in the abnormal brain circuits that contribute to Parkinson's symptoms and complications.\n\nThis study is evaluating whether treating one side of the brain or treating both sides (in separate procedures) provides better outcomes for people with advanced Parkinson's disease who have motor complications and symptoms.\n\nThe main outcome measure is the change in the MDS-UPDRS Part III Upper\u002FLower Extremity (ULE) score at 3 months after first and second side treatment, compared with the respective control groups.\n\nMDS-UPDRS Part III is a standard clinical scale used to assess Parkinson's motor symptoms. ULE score focuses on motor function in the arms and legs. Assessments are performed in the OFF-medication state, meaning Parkinson's medications are temporarily withheld so that the treatment effect can be measured more accurately.\n\nIn addition improvement in motor complications will be assessed with MDS-UPDRS Part IV and Patient diaries.",[84],"Parkinson Disease",[86,87,88],"Exablate","MRgFUS","Pallidothalamic Tract","NOT_YET_RECRUITING","2026-08-10",{"date":92,"type":93},"2026-08-14","ACTUAL",{"date":95,"type":78},"2026-09",{"date":97,"type":78},"2031-06",{"name":5,"class":6}]